Kymriah (Novartis) - LV Vector Supply
B-cell Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL)
ApprovedActive Commercial Supply
Key Facts
Indication
B-cell Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL)
Phase
Approved
Status
Active Commercial Supply
Company
About Oxford Biomedica
Oxford Biomedica is a UK-based, publicly traded CDMO that has established itself as a world leader in viral vector manufacturing for advanced cell and gene therapies. The company has transitioned to a pure-play CDMO model, leveraging its deep expertise and proprietary platforms to serve a global client base. With state-of-the-art facilities in the UK, US, and France, and a track record of over 30 years, OXB is a critical enabler for the development and commercialization of life-changing therapies, including being the first commercial supplier of lentiviral vectors for a CAR-T therapy.
View full company profile